AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.960
+0.030 (1.02%)
May 27, 2026, 12:55 PM EDT - Market open
AC Immune Employees
As of December 31, 2025, AC Immune had 122 total employees, including 90 full-time and 32 part-time employees. The number of employees decreased by 50 or -29.07% compared to the previous year.
Employees
122
Change (1Y)
-50
Growth (1Y)
-29.07%
Revenue / Employee
$37,830
Profits / Employee
-$676,680
Market Cap
293.64M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | -50 | -29.07% | 90 | 32 |
| Dec 31, 2024 | 172 | 11 | 6.83% | 133 | 39 |
| Dec 31, 2023 | 161 | 5 | 3.21% | 133 | 28 |
| Dec 31, 2022 | 156 | 7 | 4.70% | 126 | 30 |
| Dec 31, 2020 | 149 | 17 | 12.88% | 125 | 24 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Niagen Bioscience | 117 |
| Zentalis Pharmaceuticals | 106 |
| Silence Therapeutics | 88 |
| Editas Medicine | 87 |
| SAB Biotherapeutics | 86 |
| Compugen | 75 |
| Protara Therapeutics | 46 |
ACIU News
- 5 days ago - AC Immune presents new Phase 1 data on uptake of ACI-19626 - TheFly
- 5 days ago - AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS - GlobeNewsWire
- 12 days ago - Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care - GlobeNewsWire
- 15 days ago - AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM - GlobeNewsWire
- 27 days ago - AC Immune reports Q1 EPS (15c), consensus (14c) - TheFly
- 27 days ago - AC Immune First Quarter 2026 Financial and Corporate Updates - GlobeNewsWire
- 27 days ago - AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease - GlobeNewsWire
- 27 days ago - AC Immune Earnings release: Q1 2026 - Filings